LIVE WEBINAR: Wednesday, October 12, 2022, 5:00 PM – 6:30 PM Eastern Time (ET)

Challenging Cases from Junior Investigators — The Application of Available and Emerging Clinical Research in the Care of Patients with Chronic Lymphocytic Leukemia

A CE/NCPD-Accredited Virtual Event in Partnership with the 2022 Pan Pacific Lymphoma Conference

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Wednesday, October 12th for this CE/NCPD-accredited webinar
5:00 PM – 6:30 PM ET

Faculty
Danielle Brander, MD
Assistant Professor of Medicine
Director, CLL and Lymphoma Clinical Research Program
Duke University Medical Center
Durham, North Carolina

Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony R Mato, MD, MSCE
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York

William G Wierda, MD, PhD
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Wednesday, October 12, 2022
5:00 PM – 6:30 PM Eastern Time
Live CE/NCPD-accredited webinar

Topics to Be Discussed

  • MODULE 1: Current Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL)
  • MODULE 2: Rationale for and Potential Role of Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitor Combinations
  • MODULE 3: Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations
  • MODULE 4: Selection and Sequencing of Available Therapies for Relapsed/Refractory CLL
  • MODULE 5: Novel Investigational Agents and Strategies for CLL

Target Audience
This activity is intended for hematologists, medical oncologists, nurse practitioners, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and use this information to evaluate and select available front-line options.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into current treatment decision-making.
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for newly diagnosed or previously treated CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
  • Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors impact the selection and sequencing of therapy for patients with relapsed/refractory CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies employed in the management of CLL.
  • Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL and, where applicable, refer eligible patients for clinical trial participation.

Accreditation Statement
In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS: The University of Nebraska Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: The University of Nebraska Medical Center designates this activity for 1.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Credit Form
A credit form link will be emailed to each participant within 3 business days of this activity.

All credit certificates will be issued to attendees by UNMC CCE within 4 to 6 weeks after the live webcast.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. To review certification qualifications, please visit https://www.researchtopractice.com/Meetings/PanPacific22/CLL/ILNA. ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC-accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

Disclosures
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr BranderAdvisory Committee: AbbVie Inc, Genentech, a member of the Roche Group, Pfizer Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ArQule Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Catapult Therapeutics, CATO SMS, Celgene Corporation, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, Juno Therapeutics, a Celgene Company, MEI Pharma Inc, Newave Pharmaceutical Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Nonrelevant Financial Relationship: CLL Society (expert medical council), NCCN (panel member). Dr DavidsAdvisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Ono Pharmaceutical Co Ltd, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Verastem Inc; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Novartis, TG Therapeutics Inc, Verastem Inc. Dr MatoConsulting Agreements and Data and Safety Monitoring Board/Committee: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Celgene Corporation, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, Genmab, Johnson & Johnson Services Inc, Nurix Therapeutics Inc, Octapharma Plasma, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc, Verastem Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, DTRM Biopharma Co Ltd, Genentech, a member of the Roche Group, Genmab, Johnson & Johnson Services Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Octapharma Plasma, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc. Dr WierdaContracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen Therapeutics Inc, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).

CONSULTING CLINICAL INVESTIGATORSAdam S Kittai, MDAdvisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: BeiGene Ltd. Christine E Ryan, MD — No relevant conflicts of interest to disclose.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

THE UNIVERSITY OF NEBRASKA MEDICAL CENTER (UNMC) and RESEARCH TO PRACTICE (RTP) PLANNERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose: Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.

Supporters
This activity is supported by an educational grant from Genentech, a member of the Roche Group.